Effects of metformin on atrial and ventricular arrhythmias: evidence from cell to patient

Teerapat Nantsupawat1,2,3, Wanwarang Wongcharoen1,2,3, Siriporn C. Chattipakorn2,3 and Nipon Chattipakorn2,3,4*

Abstract

Metformin has been shown to have various cardiovascular benefits beyond its antihyperglycemic effects, including a reduction in stroke, heart failure, myocardial infarction, cardiovascular death, and all-cause mortality. However, the roles of metformin in cardiac arrhythmias are still unclear. It has been shown that metformin was associated with decreased incidence of atrial fibrillation in diabetic patients with and without myocardial infarction. This could be due to the effects of metformin on preventing the structural and electrical remodeling of left atrium via attenuating intracellular reactive oxygen species, activating 5′ adenosine monophosphate-activated protein kinase, improving calcium homeostasis, attenuating inflammation, increasing connexin-43 gap junction expression, and restoring small conductance calcium-activated potassium channels current. For ventricular arrhythmias, in vivo reports demonstrated that activation of 5′ adenosine monophosphate-activated protein kinase and phosphorylated connexin-43 by metformin played a key role in ischemic ventricular arrhythmias reduction. However, metformin failed to show anti-ventricular arrhythmia benefits in clinical trials. In this review, in vitro and in vivo reports regarding the effects of metformin on both atrial arrhythmias and ventricular arrhythmias are comprehensively summarized and presented. Consistent and controversial findings from clinical trials are also summarized and discussed. Due to limited numbers of reports, further studies are needed to elucidate the mechanisms and effects of metformin on cardiac arrhythmias. Furthermore, randomized controlled trials are needed to clarify effects of metformin on cardiac arrhythmias in human.

Keywords: Metformin, Arrhythmias, Atrial fibrillation, Atrial arrhythmias, Ventricular arrhythmias

Introduction

Metformin initially received approval from the U.S. Food and Drug Administration for type 2 diabetes in 1995 [1]. Since then, an accumulating body of evidence has shown various benefits of metformin beyond the antihyperglycemic effects [2]. In the case of cardiovascular protection, it has been shown that metformin exerted many benefits including a reduction in blood pressure, left ventricular mass [3], stroke [4], heart failure [5, 6], myocardial infarction (MI), cardiovascular death, and all-cause mortality [7–10]. Several mechanisms behind the cardioprotective effects have been proposed. Metformin is known as 5′ adenosine monophosphate-activated protein kinase (AMPK) activator. Metformin activates AMPK through tyrosine-protein kinase c-Src/phosphatidylinositol-3-kinase (PI3K) pathway activation [11], and/or increased AMP:ATP ratios via inhibition of mitochondrial complex 1 [12]. Once activated, AMPK stimulated endothelial nitric oxide synthase, fatty acid oxidation, glucose transport, glycolysis, cellular calcium handling, ATP-sensitive potassium channels (KATP), autophagy, and inhibited protein synthesis, cell proliferation, endoplasmic reticulum stress, endothelial lipotoxicity, and NF-kB pathway, which helped conserve/generate ATP, prevent necrosis/
Atrial fibrillation (AF) is the most common arrhythmia in clinical practice, and has been known for its progressive nature and for heightening the risk of stroke [29]. AF mainly triggered by the pulmonary veins [30] and is perpetuated by multiple wavelets [31, 32] and rotors [33, 34] in the left atrium (LA). Specific stressors, such as heart failure, diabetes, hypertension, obesity, coronary artery disease, aging, or genetic predisposition, have been shown to cause atrial dilatation, interstitial fibrosis, and shortened atrial effective refractory period (AERP) in the LA [29]. An increased atrial pressure in heart failure led to atrial dilatation and fibrosis, which is the structural substrate for AF [35]. It has been demonstrated that insulin resistance and diabetes induced structural, electrical, electro-mechanical, and autonomic remodeling in atria, which subsequently become arrhythmogenic substrates for AF [36]. An increased transforming growth factor-beta (TGF-β), connective tissue growth factor expression, and diastolic dysfunction also led to atrial dilation and fibrosis [36, 37]. An increased L-type calcium current (I_{Ca,L}), decreased connexin-43 (Cx43) expression, and reduced sodium current could lead to prolonged action potential duration (APD), increased atrial effective refractory period (AERP) dispersion, and conduction slowing [36, 37]. The combination of conduction delay and atrial fibrosis was shown to lead to excitation-contraction uncoupling [36]. Conversely, AF itself can lead to worsened heart failure due to irregular ventricular filling, loss of atrial contraction, rapid ventricular rates, and tachycardia-induced cardiomyopathy [35]; adverse LA structural remodeling, including myolysis, glycogen deposition, and electrical remodeling, resulting in the promoting of the perpetuation of AF and the setting off of a vicious cycle known as “AF begets AF” phenomenon [38, 39].

AMPK can be activated by metabolic stress and AF, and helps maintain L-type calcium channel current (I_{Ca,L}), I_{Ca,L}-triggered Ca^{2+} ion transients amplitude, sarcoplasmic reticulum Ca^{2+} content, and cell contractility [40]. Chronicity of AF affects AMPK expression in dogs and humans, with increased AMPK in paroxysmal AF, while paradoxically decreased AMPK in longstanding persistent AF [40–43]. Nonetheless, metformin has been shown to further increase AMPK expression in both situations [41, 42], along with improving insulin resistance, thus it may help prevent atrial arrhythmogenesis.

After rapid atrial pacing in non-diabetic HL-1 atrial cells, metformin was shown to prevent adverse cellular remodeling by attenuating tachy-induced myolysis and reducing intracellular reactive oxygen species (ROS) [44]. In neonatal rat cardiomyocytes, metformin attenuated rapid pacing-induced shortened field potential duration (FPD) by increasing Cx43 gap junction and zona occludens-1 (ZO-1) expression via AMPK activation [42]. Not only the direct effects on atrial cells, metformin could improve calcium homeostasis in HL-1 cells by attenuating inflammation of the co-cultured adipocytes via an increased peroxisome proliferator-activated 5'-monophosphate-activated protein kinase (AMPK) activity [14], and stimulating adenosine receptors via increased intracellular formation of adenosine [15]. Once the A1, A2A, A2B, and A3 adenosine receptors in myocardiad cells were stimulated, they coupled to G proteins and triggered a range of mostly beneficial responses. These involved activation of protein kinase C, phosphati-dylinositol-3-kinase/survival protein kinases (PI3K/Akt), and mitogen-activated protein kinase (MAPK), which ultimately targeted mitochondrial ATP-sensitive potassium (K_{ATP}) channels and limited the opening of mitochondrial permeability transition pores (mPTP), leading to protection against necrosis and apoptosis [16–18].

In diabetes-related vasculopathy, metformin was shown to decrease low-density lipoprotein-cholesterol (LDL-C) which may retard the progression of atherosclerosis [19, 20]. However, it has been shown that metformin may not reduce LDL-C, and the anti-atherosclerotic effect of metformin could be independent of lipids-lowering effect [21] and through the improved endothelial function via AMPK [22], downregulation of angiotensin II type 1 receptors, increased antioxidant superoxide dismutase-1 [23], increased cholesterol efflux in macrophages, and decreased plasminogen activator inhibitor type 1 activity, fibrinogen level, C-reactive proteins protein, and NF-kB pathway activation in the vascular wall [24–26]. Heart rate variability, which reflects sympathovagal balance and risk of cardiovascular death in diabetes [27], was also improved following metformin treatment [28].

Despite these cardiovascular benefits of metformin, the roles of metformin on the antiarrhythmic effects are still unclear. In this review, reports regarding the effects and mechanisms of metformin on cardiac arrhythmias are comprehensively summarized and presented. Consistent findings and controversial reports from in vivo and clinical studies are also presented and discussed. This information could provide an important foundation for further work on the benefits of metformin as an antiarrhythmic agent in the future.

**Effects of metformin on atrial arrhythmias: evidence from in vitro and in vivo studies**

Atrial fibrillation (AF) is the most common arrhythmia in clinical practice, and has been known for its progressive nature and for heightening the risk of stroke [29]. Specific stressors, such as perpetuated by multiple wavelets [31, 32] and rotors [33, 34] in the left atrium (LA). Specific stressors, such
receptor gamma (PPARγ)/adiponectin (APN) and suppressed tumor necrosis factor-alpha (TNFα) [45]. Metformin concentration used in the cell experiments were mostly supra-pharmacological doses. Maximal metformin approved daily dose of 2.5 g results in plasma level of 0.01–0.04 mmol/L [46], while metformin concentration used in the cell experiments ranged from 0.5 to 4 mmol/L [42, 44, 45]. Although low and high metformin concentration can both activate AMPK, the high concentration (>0.25 mmol/L) also exerted its effects through non-AMPK dependent pathways [46]. Therefore, one should be cognizant when attempting to imply mechanisms and effects of metformin from in vitro reports to clinical studies.

In non-diabetic dogs, rapid atrial pacing (AF model) increased lipid deposition in the left atrial appendages which was associated with AERP shortening and dispersion [41]. These structural and electrical changes are substrates for AF. Administration of metformin for two weeks prior to rapid atrial pacing improved fatty acid β-oxidation via the AMPK/PPAR-α/very long-chain specific acyl-CoA dehydrogenase (VLCAD) signaling pathway, resulting in decreased lipid deposition in the left atrial appendages, and therefore prevented AERP shortening/dispersion. Another study with rapid atrial pacing in dogs showed similar metformin benefits in attenuating shortened AERP, AERP dispersion, and AF reduction via AMPK/Cx43 pathway [42]. Cx43 is the predominant gap junction protein in the heart. AF caused a reduction in atrial Cx43 protein in pigs [47, 48]. Cx43 gene transfer restored atrial Cx43 protein content, improved atrial conduction, and prevented AF [47, 48]. AMPK activation promoted K_{ATP} opening and surface expression, leading to inhibition of gap junction permeability, increase Cx43 expression, and subsequently attenuate atrial arrhythmia [49].

Obesity and diabetes were independently associated with increased risk of new-onset AF. This is partly due to an expansion of epicardial adipose tissue (EAT) under these conditions [50]. EAT is in direct contact with atrial tissues. EAT infiltration and adipokines secreted by EAT could cause atrial inflammation, structural and electrical remodeling, and subsequent AF [51]. Chronic metformin for 6 weeks reduced EAT, inhibited reactive oxygen species (ROS)/NF-kB, decreased pro-inflammatory adipokines (IL-6, TNF-α, and TGF-β1), upregulated adiponectin in LA/EAT, reduced atrial fibrosis, and AF [45].

Small conductance calcium-activated potassium (SK) channels affect cardiac action potential duration during the late-phase repolarization [52]. SK channels are activated by calcium, therefore integrate intracellular calcium changes with membrane potential. SK channels express more in atrial than ventricular myocytes [52]. There are three subtypes, SK1 (K_{Ca2.1}), SK2 (K_{Ca2.2}), and SK3 (K_{Ca2.3}), which are encoded by KCNN1, KCNN2, and KCNN3, respectively [52]. Fu et al. reported an association of SK channels and atrial arrhythmias in diabetic rats [53]. They demonstrated that decreased SK2, increased SK3 expression, distorted current-voltage relationship, and overall SK current reduction in diabetic rats led to prolonged APD and subsequent atrial arrhythmias. Chronic metformin treatment for 3 months reduced atrial arrhythmias by normalizing the APD via an increased SK2, decreased SK3, increased overall SK current, and restored normal current-voltage relationship [53]. Specifically, overexpression of SK3 has been shown to be associated with heart block and atrial arrhythmias [53, 54]. Moreover, the role of SK channels in human AF was reported in genome-wide association analysis, demonstrating an association between single-nucleotide polymorphism in KCNN3 gene with lone AF [52].

In conclusion, rapid atrial pacing induced AF via structural (increased ROS, myolysis, lipid deposition, left atrial fibrosis) and electrical (shortened AERP, increased AERP dispersion) remodeling. Metformin was shown to attenuate this adverse remodeling and break in the “AF begets AF” process. Despite limited in vitro and in vivo reports as summarized in Tables 1 and 2, these in vitro and in vivo studies consistently supported the beneficial effects of metformin on atrial arrhythmias via protection against atrial structural and electrophysiological remodeling in both diabetic and non-diabetic settings. Figure 1 summarized mechanisms behind the protective effects of metformin on atrial arrhythmias.

Effects of metformin on atrial arrhythmias: evidence from clinical trials
Observational studies demonstrated that metformin was associated with a reduction in AF incidence, when compared to other anti-diabetic medications, among patients who had diabetes or presented with acute MI [44, 55, 56]. However, the anti-atrial arrhythmias effects seemingly vanished in patients of older age (>65 years old) or had more advanced diabetes [44, 55, 57]. One study has shown an association between longer DM duration and more advanced atrial remodeling [58]. Older age is known to be associated with more comorbidities (e.g. coronary artery disease, congestive heart failure, hypertension), more fibrous tissue interspersed between myocytes, and electrophysiologic changes of LA [59, 60]. These factors could contribute to the fewer anti-AF effects of metformin seen in these populations. Due to the limitations as an observational cohort, the dose and duration of metformin used in these studies varied and were not reported in detail, thus limiting the analysis of adequacy of dosage and treatment duration.
Table 1: Effects of metformin on atrial arrhythmias: reports from in vitro studies

| Model | Metformin (dose/duration) | Key results and major findings | Interpretation | References |
|-------|---------------------------|-------------------------------|----------------|------------|
|       |                           | Energy homeostasis | Oxidative stress | Intra-cellular Ca | Inflammation | Cx43 | EP changes | Cell structure |                |
| HL-1 atrial cells paced with 4 Hz (240 bpm) for 24 h | 1 mmol/L for 2 h | ↓ROS | – | – | – | – | – | ↑Cytoplasmic myosin heavy chain/nuclear area ratio | Metformin provided cardioprotection against AF-related adverse remodeling via attenuating tachy-induced myolysis and oxidative stress of atrial cells | [44] |
| Neonatal rat cardiomyocytes and HL-1 cell with field stimulation at 3 Hz for 12 h | 0.5 & 1 mmol/L | ↓cAMP → ↓pSrc → ↑AMPK → ↑Cx43 | – | – | – | ↑ | ↑FPD | ↑ZO-1 | Metformin attenuated a shortened FPD possibly by improved gap junction function via AMPK activation, increased ZO-1 and Cx43 expression | [42] |
| 3T3-L1 mature adipocytes with LPS for 24 h then co-cultured with HL-1 atrial cell | 4 mmol/L incubated with adipocytes for 12 h | ↓Ca, ↑SERCA2a, ↑pPLN in HL-1 cell, ↑PPARγ/APN, and ↓TNFα in adipocytes | – | – | – | – | – | Metformin improved Ca\(^ {2+}\) homeostasis in HL-1 cell by attenuated the inflammatory interaction between adipocytes and HL-1 cell via an increased PPARγ/APN and suppressed TNFα | [45] |

*AMPK S’ adenosine monophosphate-activated protein kinase, APN adiponectin, Ca calcium, cAMP cyclic adenosine monophosphate, Cx43 connexin 43, FPD field potential duration, LPS lipopolysaccharide, PPARγ peroxisome proliferator-activated receptor gamma, pPLN phosphorylated phospholamban, p-Src phopho-Src(Tyr416), ROS reactive oxygen species, SERCA2a sarcoplasmic reticulum Ca\(^ {2+}\)−ATPase2a, TNFα tumor necrosis factor alpha, ZO-1 Zonula occludens-1*
Table 2: Effects of metformin on atrial arrhythmias: reports from in vivo studies

| Model                     | Metformin (dose/duration) | Key results and major findings | Interpretation                                                                                                                                                                                                 | References |
|---------------------------|---------------------------|-------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
|                           |                           | Energyhomeostasis | ROS | lonchannel | Inflammation | Cx43 | EP changes | Structuralremodel | AF |                           |
| Non-DM dogs with atrial rapid pacing (1200 bpm for 6 h) | 100 mg/kg/days for 2 weeks | ↑↑ AMPK  ↑ PPARα, PGC-1α, VLCAD, CPT-1 | – | – | – | – | ↑ AERP | ↓ AERPd | ↓ FFA/TG/lipid deposition in LAA | – | Metformin improved EP disorders caused by atrial rapid pacing via ↓ lipid accumulation and promoted FAO in AF models through AMPK/PPAR-α/VLCAD pathway | [41]|
|                           |                           | – | ↓ | – | ↑ APN, adipor1 | – | ↓ IL-6, NF-κB, TNFα, TGFβ1 | – | ↑ AERP | ↓ AERPd | ↓ LA fibrosis and EAT | ↓ | Metformin reduced AF and atrial fibrosis by inhibited ROS/NF-κB, reduced epicardial fat, pro-inflammatory adipo kines, and upregulated adiponectin in LA/EAT | [45]|
| Non-DM dogs with rapid atrial pacing (400 bpm for 6 weeks) | 100 mg/kg/days for 1 week prior then 6 weeks | – | – | ↓ | – | – | ↑ APN, adipor1 | – | ↓ IL-6, NF-κB, TNFα, TGFβ1 | – | Metformin reduced AF by preventing adverse electrical remodeling via increase AMPK and Cx43 expression in chronic AF model. Metformin mildly increased Cx43 in acute pacing and could not attenuate AERPd | [42]|
| Non-DM dogs with rapid atrial pacing 400 bpm | 100 mg/kg/days for 1 week then pace for 180/360 min (acute) | ↑ AMPK ↔ mitochondrial morphology | – | – | – | – | ↑ AERP | ↔ Irregular myocardial fibers | – | Metformin reduced atrial arrhythmia in DM GK rats via decreased atrial remodeling and normalized APD via restoring SK current | [53]|
|                           | 100 mg/kg/days with pace for 6 weeks (chronic) | – | – | – | – | ↑ AERP | ↔ Irregular myocardial fibers | – | Metformin reduced atrial arrhythmia in DM GK rats via decreased atrial remodeling and normalized APD via restoring SK current | [53]|
| GKT2DM rats               | 300 mg/kg/days for 3 months | – ↔ SK1, ↑ SK2, ↓ SK3 | ↓ SK current | ↓ distorted current-voltage relationship | – | ↓ APD | ↓ Atrial myofilament irregularity and fibrosis | – | Metformin reduced atrial arrhythmia in DM GK rats via decreased atrial remodeling and normalized APD via restoring SK current | [53]|

adipor1 adiponectin receptor 1, AERP atrial effective refractory period, AERPd AERP dispersion, AMPK 5’-adenosine monophosphate-activated protein kinase, APD action potential duration, bpm beats per minutes, APN adiponectin, Ca calcium, CPT-1 Carnitine palmitoyltransferase I, EAT epicardial adipose tissue, EP electrophysiologic, FFA free fatty acid, GK Goto-Kakizaki, LA left atrium, LAA left atrial appendage, PGC-1α peroxisome proliferator-activated receptor-gamma coactivator 1α, PPAR-α peroxisome proliferator-activated receptor α, ROS reactive oxygen species, SK channel’s small conductance calcium-activated potassium channels, TG triglyceride, TGFβ1 transforming growth factor beta 1, TNFα tumor necrosis factor alpha, VLCAD Very long-chain specific acyl-CoA dehydrogenase
AF following cardiac surgery occurs not uncommonly with an incidence ranged from 5–64%, and it is associated with prolonged hospital stay, extra cost of care, greater in-hospital mortality, and worse long-term survival [61]. Several mechanisms have been proposed to be accountable for post cardiac surgery AF, including perioperative inflammation, pericarditis, electrical remodeling, autonomic imbalance, atrial incision, perioperative ischemia, and increased oxidative stress [61, 62]. Since metformin has been shown to exert benefits on reducing oxidative stress and inflammation [23, 26, 44, 63–67], it was expected that it might reduce AF in these circumstances.

Unfortunately, a randomized controlled trial of 3-day metformin treatment before surgery did not decrease troponin I level or incidence of post cardiac surgery AF in patients without diabetes as compared to placebo [68]. Consistent with this report, metformin was also not associated with decreased post cardiac surgery AF in a retrospective cohort of matched DM patients [69]. Although no in vitro or in vivo studies had directly looked at the performance of metformin on atrial arrhythmias under post cardiac surgery circumstances, these results may imply an ineffectiveness of metformin in preventing AF in post cardiac surgery in the case of both diabetic and

---

**Fig. 1** Effects of metformin on atrial arrhythmias. Atrial fibrillation, obesity, insulin resistance, and diabetes mellitus can cause atrial structural, electrical, electromechanical, and autonomic adverse remodeling. These remodelings become arrhythmogenic substrates and set out a vicious cycle known as “AF begets AF”. Metformin exerts protective effects through various mechanisms. Red arrow shows adverse effects from atrial fibrillation, obesity, insulin resistance, and diabetes. Green rectangle shows pathway that metformin blocked. Solid green arrow shows protective mechanisms of metformin directly demonstrated from the studies in Tables 1 and 2. Dotted green arrow indicates protective mechanism of metformin from other studies in the text.
non-diabetic patients. All of these reports are summarized in Table 3.

**Effects of metformin on ventricular arrhythmias: evidence from in vivo studies**

Ventricular arrhythmias, which include ventricular tachycardia and ventricular fibrillation (VT/VF), can occur from ischemic and reperfusion (I/R) injury, post-myocardial infarction scar-related reentry, cardiac channelopathy, medication-induced long QT syndrome, or idiopathic [70]. Increased QT interval and QT dispersion reflects prolonged repolarization and inhomogeneity of repolarization, respectively [71]. In diabetes, there are increased corrected QT (QTc) interval and QT dispersion possibly due to alterations in voltage-gated potassium channels [72, 73] and L-type calcium channels [74], and these were associated with a higher risk of sudden cardiac death [75–77]. In animal models, metformin was shown to decrease QT dispersion, and reduce APD and QT interval by inhibiting I_{Ca,L} [78, 79]. Post-myocardial infarction ventricular arrhythmias occur from reentry around the scarred and slow-conduction myocardial tissues [70]. Administration of metformin for 2 weeks prior to MI induction in mice could reduce cardiac conduction delay (prolonged PR, QT interval, APD, and conduction velocity), rescue inwardly rectifying potassium channel 2.1 (Kir2.1), and increased Cx43 expression by regulating microRNA-1 overexpression [80]. I/R injury performed in animal studies can largely be divided into 2 models, one with partial occlusion of coronary flow or a non-ST elevation myocardial infarction (NSTEMI) I/R model, and another one with total occlusion of coronary flow or ST elevation myocardial infarction (STEMI) I/R model.

In the STEMI I/R rat model, chronic metformin treatment for 3 weeks has been shown to improve cardiac mitochondrial function, intracellular calcium handling, left ventricular pressure rise (LV dP/dt), and heart rate variability [63]. It also reduced markers for oxidative stress (Malondialdehyde- MDA) and infarct size. However, chronic metformin treatment alone was not able to reduce arrhythmia score or mortality rate [63]. Only when chronic metformin treatment was combined with vildagliptin, could the combination increase phosphorylated Connexin43 (pCX43), and consequently delay time to first VT/VF onset, and reduce arrhythmia score, and mortality rate [63]. In addition, there was no difference of plasma glucose level between the control and the treatment groups, suggesting a direct anti-arrhythmic effect of metformin/vildagliptin beyond an anti-hyperglycemia [63]. These findings are consistent with other studies that showed the importance of the role of pCX43 in the pathogenesis of VT/VF in STEMI models [81–85]. Although studies have been performed in STEMI I/R rodent models which showed the beneficial effects of acute metformin administration (18 h to 2 days prior to ischemia), in reducing infarct size and improving LVEF, arrhythmic outcomes were not measured [14, 86, 87].

In a NSTEMI I/R pig model, acute injection of metformin 3 h prior to ischemia did not provide any benefits regarding AMPK activation, LV dP/dt, electrophysiological changes, and most importantly VT/VF incidence [88]. Unlike acute metformin treatment, chronic metformin treatment for 2–3 weeks in a partial coronary artery occlusion model was shown to reduce VT/VF incidence by preventing monophasic action potential shortening and reducing the dispersion of action potential duration between the ischemic/infarct area and normal myocardium via AMPK activation, leading to preservation of myocardial ATP [88]. The anti-VT/VF effect of metformin was not related to a reduction in blood glucose because it was continuously maintained during the experiments at 4.5 ± 0.5 mmol/L with 10% dextrose solution in both control and treatment groups [88].

Evidence from these in vivo reports suggested that chronic treatment with metformin alone might reduce VT/VF incidence in the NSTEMI model, whereas the combination of chronic metformin and vildagliptin was required in order to reduce VT/VF in the STEMI model. In contrast, acute metformin treatment did not have any effect on VT/VF events in the NSTEMI model. However, acute metformin treatment was not tested in the STEMI model. All of these reports are summarized in Table 4.

Figure 2 summarized mechanisms behind the protective effects of metformin on ventricular arrhythmias.

**Effects of metformin on ventricular arrhythmias: evidence from clinical trials**

Patients presented with VT/VF who had diabetes portend worse long-term all-cause mortality at 2 years as compared to patients without diabetes [89]. Hyperglycemia was associated with prolonged QT interval, increased QT dispersion, and higher risk of developing VT in acute MI patients [90, 91]. Whether hyperglycemia is the cause of ventricular arrhythmias, or merely a marker of increased sympathetic activity remains uncertain [92]. Although metformin was associated with a decrease in QTc in diabetic patients [93], there was no available data regarding the relationship between achieving acute hyperglycemic control with metformin/anti-diabetic medications and ventricular arrhythmic outcomes.

There were only two clinical trials that directly studied the effects of metformin on ventricular arrhythmias [56, 94]. In a randomized crossover trial, 19 diabetic patients with coronary artery disease (CAD) were randomized to receive either metformin 500 mg twice daily for 2 weeks or placebo. The primary outcomes
### Table 3 Effects of metformin on atrial arrhythmias: reports from clinical trials

| Model | Type of study/No. of patients/follow-up | Metformin (dose/duration) | AF incidence | Interpretation | References |
|-------|----------------------------------------|---------------------------|--------------|----------------|------------|
| Taiwanese DM patients treated with metformin alone vs. other meds (mean age 58 years) | Longitudinal cohort/85,198 metformin users and 560,512 non-users/ mean follow-up 5.4 years | Various dose and duration of metformin | ↓ AF incidence in the first 3 years after diagnosis of DM | HR of 0.81, p < 0.0001 | [44] |
| Taiwanese DM patients w/ or w/o metformin (mean age 69 years) | Nested case control study/2882 AF and 11,528 controls/mean DM duration 3.9 years | - Various dose - At least 6 months of drug used | ↓ AF incidence | OR 0.81, 95% CI 0.71–0.95 | [55] |
| Hospitalized DM patients with AMI w/ or w/o metformin (mean age 56) | Retrospective cohort/40 Metformin alone and 705 others/28-day post AMI | Various dose | ↓ AF incidence | OR 0.2 (95% CI 0.1–0.7) | [56] |
| ≥65 years old Taiwanese DM patients w/ or w/o metformin (mean age 73 years) | Nested case-control/1958 cases and 7832 controls/mean DM duration 8 years | Various dose - At least 12 months of drug used | ↓ AF incidence | OR 1.01 (0.88–1.15) | [57] |
| Patients without DM undergoing cardiac surgery randomized to metformin or placebo (mean age 65 years) | Double-blind, randomized controlled trial/57 to metformin, 57 to placebo/24-h post reperfusion | Metformin 500 mg TID for 3 days before surgery | ↓ 24-h post reperfusion Trop I level and arrhythmia | | [68] |
| DM pts undergoing cardiac surgery w/ or w/o metformin (mean age 66 years) | Retrospective matched cohort/metformin 635, non-metformin 648/post-op until hospital discharge | Metformin ≥ 500 mg any time prior to surgery | ↓ post-op AF incidence | post-op AF 26.3% in metformin vs. 30.7% in non-metformin (p = 0.46) | [69] |

AF: atrial fibrillation, AMI: acute myocardial infarction, DM: diabetes mellitus
Table 4: Effects of metformin on ventricular arrhythmias: reports from in vivo studies

| Model | Metformin (dose/duration) | Key results and major findings | Interpretation | References |
|-------|--------------------------|-------------------------------|----------------|------------|
| Domestic farm pigs with cardiac I/R injury - (50% flow)/R = 90/45 min | - Chronic metformin 30 mg/kg/day oral for 2–3 weeks | - ↑↑AMPK - ↑CS - ↑ATP - <-> O2, glucose use, lactate | - ↓MAP shortening - ↓APD dispersion | [88] |
| | - Acute Metformin N’ 100 mg/kg | - <-> AMPK | - - | - <-> |
| Male Wistar rats fed with high fat for 12 weeks underwent cardiac I/R injury (LAD ligation 30/R 120 min) | Metformin 30 mg/kg/day for 3 weeks | ↑ Mito-chondrial function ↓ MDA ↑ Diastolic Ca ↑ Transient amp/decay | ↓Infarct/ ↓Bax, ↑Bcl-2 ↑HRV | [63] |
| | Metformin + Vildagliptin | ↑ Mito-chondrial function ↓ MDA ↑ Diastolic Ca ↑ Transient amp/decay | ↓Infarct/ ↓Bax, ↑Bcl-2 ↑HRV | ↑ ↓ |

AMPK 5′adenosine monophosphate-activated protein kinase, APD action potential duration, ATP adenosine triphosphate, Ca calcium, CS citrate synthase, EP electrophysiologic, HRV heart rate variability, I/R ischemic/reperfusion, LAD left anterior descending coronary artery, LV left ventricular, MAP monophasic action potential, MDA malondialdehyde, pAMPK phosphorylated 5′adenosine monophosphate-activated protein kinase, p-Cx phosphorylated Connexin, VT/VF ventricular tachycardia/ventricular fibrillation
were number of premature ventricular contractions/non-sustained VT (PVC/NSVT) beats measured by 24-h Holter monitor [94]. Metformin failed to reduce PVC/NSVT in diabetic CAD patients compared to placebo [94]. However, the results should be interpreted with caution due to the small sample size and a lower-than-average dosage (1000 mg per day) [94] as compared to other studies with cardiovascular benefits (1700–2000 mg per day) [8]. Also, this particular study was not performed under ischemic/reperfusion circumstances, which may explain why metformin did not reveal its anti-ventricular arrhythmia benefits as opposed to the positive findings reported in an animal I/R injury model [88]. Therefore, the PVC/NSVT may be associated with mechanisms other than ischemia, such as automaticity or triggered activity, and might not indicate a poor prognosis.

The second study was a retrospective cohort of hospitalized diabetic patients who presented with acute MI [56]. Unfortunately, metformin was not associated with decreased VT/VF incidence within 28-days post MI [56]. Similar to the first report mentioned above, this report has several limitations, including no data regarding type of MI, unreported metformin dosage and duration, and underutilized beta blocker (23%) and thrombolytic reperfusion therapy (21%). All of these reports are summarized in Table 5.

**Ongoing trials and future research**

Two ongoing studies are being carried out regarding the effects of metformin on AF. The first study is a phase 4 randomized open-label study aiming to see whether metformin as compared to placebo could reduce AF burden in patients with paroxysmal or persistent AF who have cardiovascular implantable electronic devices (NCT03603912, TRIM-AF study) [95]. The second study was a phase 2 randomized clinical trial which aimed to see whether metformin could help AF patients stay within a normal sinus rhythm after catheter ablation. This second study had an early termination due to unmet enrollment expectations (NCT02931253) [96]. Unfortunately, there is no ongoing clinical trial of the effects of metformin on ventricular arrhythmias (Table 6).

To progress from the in vivo AF studies, it might be helpful to examine the role of metformin in AF trigger. Since the available reports only assessed AF inducibility and duration after rapid atrial pacing [42, 45], or spontaneous AF detected by surface electrocardiogram [53], this information is not sufficient to determine whether metformin reduced AF by suppressing pulmonary vein

---

**Fig. 2** Effects of metformin on ventricular arrhythmias. Ischemia causes reduction in myocardial ATP and finally results in ventricular fibrillation. Chronic metformin use exerts its energy guardian effects mainly via AMPK activation. Additionally, metformin prevents QT interval prolongation, QT dispersion, and conduction velocity delay by regulating microRNA-1 and L-type calcium channels. Only the combination of metformin and vildagliptin could increase p-Cx43 and subsequently reduce ventricular fibrillation. Green rectangle and arrow shows protective mechanisms of metformin.
triggers or modulating reentry substrate. For in vivo ventricular arrhythmia study, it would be of interest to see whether metformin alone or in combination with a dipeptidyl peptidase-4 inhibitor could reduce ventricular arrhythmias or sudden cardiac death in acute coronary syndrome patients. These hypotheses remain to be elucidated in the future clinical studies.

Although there are some borderline or contradictory results, ample scientific evidence exists to indicate that metformin has potential beneficial effects with regard to atrial and ventricular arrhythmias in human. Adequately-powered randomized controlled trials are needed to clarify the actual effects of metformin both in diabetic and non-diabetic populations. In the case of a study into atrial arrhythmias, use of continuous rhythm monitoring devices, such as an implantable loop recorder, pacemaker, or defibrillator, is strongly encouraged in order to avoid underdetection of AF.

**Conclusions**

Basic research has demonstrated the protective effects of metformin on both atrial and ventricular arrhythmias via multiple molecular, cellular, electrophysiological, and structural changes. These findings are mostly translated into anti-atrial arrhythmic benefits seen in clinical trials. However, there are exception in some instances, such as in elderly diabetic or post cardiac surgery patients. Currently, there are very limited clinical reports on the effects of metformin on ventricular arrhythmias and the number of ongoing trials is very small. At this point, proper randomized controlled trials are of the utmost importance in order to clarify the beneficial effects of metformin on cardiac arrhythmias.

---

**Table 5** Effects of metformin on ventricular arrhythmias: reports from clinical trials

| Model | Type of study/No. of patients/FU | Metformin (dose/duration) | Key results and major findings | Interpretation | References |
|-------|---------------------------------|---------------------------|------------------------------|----------------|------------|
| DM patients with CAD monitored via 24-h Holter monitor (mean age 55) | Randomized crossover design/19 patients/2 weeks | Metformin 500 mg BID for 2 weeks | <-> PVC/NSVT per minute of ischemia | Metformin did not reduce PVC/NSVT in diabetic CAD patients | [94] |
| Hospitalized DM patients with AMI (mean age 56) | Retrospective cohort/40 Metformin alone and 705 others/28-day post AMI | Various doses | <-> 28-days VT/VF incidence | Metformin alone or in combination with other anti-DM drugs was not associated with decreased 28-day post AMI VT/VF incidence | [56] |

AMI acute myocardial infarction, CAD coronary artery disease, DM diabetes mellitus, PVC/NSVT premature ventricular contraction/non-sustained ventricular tachycardia, VT/VF ventricular tachycardia/ventricular fibrillation

**Table 6** Effect of metformin on arrhythmias: ongoing clinical trials

| Model | Status | Type of study/No. of patients/FU | Intervention | Primary outcome | References |
|-------|--------|---------------------------------|--------------|----------------|------------|
| Patients with paroxysmal or persistent AF with CIED | Recruiting | Phase 4 Randomized clinical trial/270 patients/2 years | - Metformin 750 mg twice daily × 2 years - Lifestyle/risk factor modification | Change in %AF burden at 1 year | [95] |
| Patients with AF who underwent AF catheter ablation | Terminated | Phase 2 Randomized clinical trial/6 patients/6 months | - Metformin 1000 mg twice daily | Number of patients who maintain sinus rhythm | [96] |

AF atrial fibrillation, CIED cardiovascular implantable electronic device
Abbreviations
AERP: Atrial effective refractory period; AF: Atrial fibrillation; AMPK: 5′ adenosine monophosphate-activated protein kinase; APD: Action potential duration; APN: Adiponectin; CAD: Coronary artery disease; CaH3: Connexin-43; DM: Diabetes mellitus; EAT: Epicardial adipose tissue; FPD: Field potential duration; ICa,L: L-type calcium current; I/R: Ischemic and reperfusion; KATP channel: ATP-sensitive potassium channel; LA: Left atrium; LDL-C: Low-density lipoprotein-cholesterol; LV dP/dt: Left ventricular pressure rise; LVEF: Left ventricular ejection fraction; MAPK: Mitogen-activated protein kinase; MDA: Malondialdehyde; MI: Myocardial infarction; mPTP: Mitochondrial permeability transition pores; NSTEMI: Non-ST elevation myocardial infarction; NSVT: Non-sustained ventricular tachycardia; pACh: Phosphorylated connexin; P3K/Akt: Phosphatidylinositol-3-kinase/survival protein kinases; PPAR: Peroxisome proliferator-activated receptor; PVC: Premature ventricular contraction; QTc: Corrected QT interval; ROS: Reactive oxygen species; SK current: Small conductance calcium-activated potassium current; STEMI: ST elevation myocardial infarction; TGF-β: Transforming growth factor-beta; TNFα: Tumor necrosis factor alpha; VLDL: Very long-chain specific acyl-CoA dehydrogenase; VT/VF: Ventricular tachycardia and ventricular fibrillation; ZO-1: Zonula occludens-1.

Acknowledgements
Not applicable.

Authors’ contributions
TN, SCC, and NC participated in the conception and the design of the review. TN, WW, SCC, and NC wrote the manuscript. TN and NC revised the whole writing process. All authors read and approved the final manuscript.

Funding
This work was supported by the NSTDA Research Chair grant from the National Science and Technology Development Agency Thailand (NC), the Senior Research Scholar grant from the National Research Council of Thailand (SCC), the Thailand Science Research and Innovation (TSRI) grant (NC), and the Chiang Mai University Center of Excellence Award (NC).

Availability of data and materials
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Author details
1 Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. 2 Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Chiang Mai 50200, Thailand. 3 Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai, Thailand. 4 Cardiac Electrophysiology Unit, Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

Received: 24 July 2020 Accepted: 15 November 2020 Published online: 24 November 2020

References
1. Bristol-Myers Squibb Company. Metformin HCL (Glucophage) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020357Orig1s000rev.pdf. Initial approval 1995.
2. Rojas LB, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr. 2013;5(1):6.
3. Mohan M, Al-Talabany S, McKinnie A, Mordi IR, Singh JSS, Gandy SJ, Baig F, Hussain MS, Bhalraam U, Khan F; et al. A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial. Eur Heart J. 2019;40(41):3409–17.
4. Cheng YY, Leu HB, Chen TJ, Chen CL, Kuo CH, Lee SD, Kao CL. Metformin-inclusive therapy reduces the risk of stroke in patients with diabetes: a 4-year follow-up study. J Stroke Cerebrovasc Dis. 2014;23(2):e99–105.
5. Nichols GA, Koro CE, Gullion CM, Ephraim SA, Brown JB. The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev. 2005;21(1):51–7.
6. Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Attreja A, Zimmerman RS. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol. 2009;46(2):145–54.
7. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34): UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352(9131):854–865.
8. Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2011;13(3):221–8.
9. Han Y, Xie Y, Liu Y, Gao P, Yang X, Shen Z. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol. 2019;18(1):96.
10. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28(10):2345–51.
11. Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN. Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol. 2010;162(2):193–212.
12. Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin in diabetes: a paradigm shift in cardiovascular disease management. Basic Clin Pharmacol Toxicol. 2008;103(1):82–7.
13. Young LH. AMP-activated protein kinase conducts the ischemic stress response of the heart. Circulation. 2008;117(6):832–40.
14. Solskov L, Løføren B, Kristiansen SB, Jessen N, Pold R, Nielsen TT, Botker HE, Schmitz O, Lund S. Metformin induces cardioprotection against ischaemia/reperfusion injury in the rat heart 24 hours after administration. Basic Clin Pharmacol Toxicol. 2008;103(1):82–7.
15. Paiva M, Riksen NP, Davidson SM, Hausenloy DJ, Monteiro P, Gonçalves L, Providencia L, Rongen GA, Smits P, Mocanu MM, et al. Metformin prevents myocardial reperfusion injury by activating the adenosine receptor. J Cardiovasc Pharmacol. 2009;53(5):373–8.
16. Peart JN, Headrick JP. Adenosineergic cardioprotection: multiple receptors, multiple pathways. Pharmacol Ther. 2007;114(2):208–21.
17. El Messaoudi S, Rongen GA, de Boer RJ, Riksen NP. The cardioprotective effects of metformin. Curr Opin Lipidol. 2011;22(6):445–53.
18. Whitington HU, Hall AR, McLaughlin CR, Hausenloy DJ, Yellow DA, Mocanu MM. Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon. Cardiovasc Drugs Ther. 2013;27(1):5–16.
19. Glueck CJ, Fontaine RN, Wang P, Subbiah MT, Weber K, Illig E, Streicher P, Sieve-Smith L, Tracy TM, Lang JE, et al. Metformin reduces weight, central obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism. 2001;50(7):856–61.
20. Goldberg R, Temprosa M, Otvos J, Brunzell J, Marcovina S, Mather K, Arakaki R, Watson K, Horton E, Barrett-Connor E. Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program. J Clin Endocrinol Metab. 2013;98(10):3989–98.
21. Luo F, Das A, Chen J, Wu P, Li X, Fang Z. Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management. Cardiovasc Diabetol. 2019;18(1):54.
22. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol. 2001;37(5):1344–50.
23. Fotouzandeh F, Salazar G, Patrushev N, Xiong S, Hilenksi L, Fei B, Alexander RW. Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis. J Am Heart Assoc. 2014;3(6):e001202.
24. Luo F, Guo Y, Ruan GY, Long JK, Zheng XL, Xia Q, Zhao SP, Peng DQ, Fang ZF, Li XP. Combined use of metformin and atorvastatin attenuates atherosclerosis in rabbits fed a high-cholesterol diet. Sci Rep. 2017;7(1):2169.

25. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and platelet activation inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care. 1993;16(4):621–9.

26. Sobel BE, Hardison RM, Greshn S, Brooks MM, McBane RD 3rd, Schneider DJ, Pratley RE, Huber K, Wolk R, Krishnaswami A, et al. Profibronolytic, antiatherogenic, and antifibrotic effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetic (BARI 2D) trial. Circulation. 2011;124(12):703.

27. Huijbers HV, Steen PK. Heart rate variability in risk stratification of cardiac patients.Prog Cardiovasc Dis. 2013;56(2):153–9.

28. Manzella D, Grella R, Esposito K, Giugliano D, Barbagallo M, Paolizzo G. Blood pressure and cardiac autonomic nervous system in obese type 2 diabetic patients: effect of metformin administration. Am J Hypertens. 2004;17(3):223–7.

29. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Chambers JK, Delgado V, Di Lenarda A, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(28):2893–962.

30. Haisaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garigue S, Le Mouroux A, Le Metayer P, Clementy J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339(10):659–66.

31. Cox JL, Kanavane TE, Schuessler RB, Cain ME, Lindsay BD, Stone C, Smith PK, Corr PB, Boineau JQ. The surgical treatment of atrial fibrillation. II. Intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation. J Thorac Cardiovasc Surg. 1991;101(3):406–26.

32. Moe GK, Abildskov JA. Atrial fibrillation as a self-sustaining arrhythmia independent of focal discharge. Am J Cardiol. 1959;58(1):159–70.

33. Haisaguerre M, Hocini M, Denis A, Shah AJ, Komatsu Y, Yamashita S, Daly M, Amraoui S, Zellerhoff S, Picat MQ, et al. Driver domains in persistent atrial fibrillation. Circulation. 2019;181(12):1211–23.

34. Narayan SM, Krummen DE, Shivkumar K, Clopton P, Rappel WJ, Miller JM. Atrial fibrillation in awake, chronically instrumented goats: canine atrial fibrillation provides a substrate for arrhythmogenesis. Cardiovasc Res. 2005;66(2):353–63.

35. Bai F, Liu Y, Tu T, Li B, Xiao Y, Ma Y, Qin F, Xie J, Zhou S, Liu Q. Metformin regulates lipid metabolism in a canine model of atrial fibrillation through AMPK/PPAR-alpha/VLCAD pathway. Lipids Health Dis. 2019;18(1):109.

36. Wang A, Green JB, Halperin JL, Piccini JP. Atrial fibrillation and diabetes mellitus: JACC review topic of the week. J Am Coll Cardiol. 2014;63(18):1865–76.

37. Davis TM, Parsons RW, Broadhurst RJ, Hobbs MS, Jamrozik K. Arrhythmias and new-onset atrial fibrillation: a population-based nested case-control study. PLoS One. 2018;13(8):e0197245.

38. Davis TM, Parsons RW, Broadhurst RJ, Hobbs MS, Jamrozik K. Arhythmias and mortality after myocardial infarction in diabetic patients. Relationship to diabetes treatment: Diabetes Care. 1998;21(4):637–40.

39. Chen HY, Yang FY, Chu CY, Yen HH, See LC. Association of metformin with lower atrial fibrillation risk among patients with obesity and diabetes who have atrial fibrillation: the potential mediating influence of epicardial adipose tissue. Cardiovasc Diabetol. 2019;18(1):63.

40. Apaijai N, Chinda K, Palee S, Chattipakorn S, Chattipakorn N. Combined use of metformin and atorvastatin attenuates atherosclerosis in rabbits fed a high-cholesterol diet. Sci Rep. 2017;7(1):2169.

41. Anyukhovsky EP, Sosunov EA, Chandra P, Rosen TS, Boyden PA, Danilo P, Schwinn DA, Moskowitz AL. AMPK/PPAR-alpha/VLCAD pathway. Lipids Health Dis. 2019;18(1):109.

42. Qiu J, Zhou S, Liu Q. Phosphorylated AMP-activated protein kinase slows the rate of myocardial infarction in diabetic patients. Circulation. 2012;125(2):1845–51.

43. Fu X, Pan Y, Cao Q, Li B, Wang S, Du H, Duan N, Li X. Metformin restores electrophysiology of small conductance calcium-activated potassium channels in the atrium of GK diabetic rats. BMC Cardiovasc Disord. 2018;18(1):63.

44. Zhang XD, Lieu DK, Chiamvimonvat N. Small-conductance Ca2+-activated K+ channels and cardiac arrhythmias. Heart Rhythm. 2015;12(8):1845–51.

45. Igarashi T, Finet JE, Takeuchi A, Fujino Y, Strom M, Greener ID, Rosenbaum DS, Donahue JK. Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation. Circulation. 2012;125(2):216–25.

46. Qiu J, Zhou S, Liu Q. Phosphorylated AMP-activated protein kinase slows down the atrial fibrillation progression by activating Connexin43. Int J Cardiol. 2016;208:56–7.

47. Kim YG, Han KD, Choi JH, Boo KY, Kim DY, Oh SK, Lee KH, Shin J, Kim JS, Kim YH. The impact of body weight and diabetes on new-onset atrial fibrillation: a nationwide population based study. Cardiovasc Diabetol. 2019;18(1):128.

48. Kim YG, Han KD, Choi JH, Boo KY, Kim DY, Oh SK, Lee KH, Shin J, Kim JS, Kim YH. The impact of body weight and diabetes on new-onset atrial fibrillation: nationwide population-based study. Cardiovasc Diabetol. 2019;18(1):128.

49. Packard M. Disease-treatment interactions in the management of patients with obesity and diabetes who have atrial fibrillation: the potential mediating influence of epicardial adipose tissue. Cardiovasc Diabetol. 2019;18(1):121.

50. Davis TM, Parsons RW, Broadhurst RJ, Hobbs MS, Jamrozik K. Arhythmias and new-onset atrial fibrillation: a population-based nested case-control study. PLoS One. 2018;13(8):e0197245.

51. Williams CM, Parsons RW, Broadhurst RJ, Hobbs MS, Jamrozik K. Arhythmias and mortality after myocardial infarction in diabetic patients. Relationship to diabetes treatment: Diabetes Care. 1998;21(4):637–40.

52. Chen HY, Yang FY, Chu CY, Yen HH, See LC. Association of metformin with lower atrial fibrillation risk among patients with obesity and diabetes who have atrial fibrillation: the potential mediating influence of epicardial adipose tissue. Cardiovasc Diabetol. 2019;18(1):63.

53. Apaijai N, Chinda K, Palee S, Chattipakorn S, Chattipakorn N. Combined use of metformin and atorvastatin attenuates atherosclerosis in rabbits fed a high-cholesterol diet. Sci Rep. 2017;7(1):2169.
metformin protect diabetic patients from oxidative stress and leukocyte-endothelium interactions? Antioxid Redox Signal. 2017;27(17):1439–45.

66. Esteghamati A, Eiskandari D, Mirimparpour H, Noshad S, MousaviSadzech M, Hedayati M, Nakhjavani M. Effects of metformin on markers of oxidative stress and antioxidant reserve in patients with newly diagnosed type 2 diabetes: a randomized clinical trial. Clin Nutr. 2013;32(2):179–85.

67. Malinska H, Oliyarnyk O, Skop V, Silhavy J, Landa V, Zidek V, Mlejnek P, Simaková M, Strnad H, Kázdová L, et al. Effects of metformin on tissue oxidative and Dicarbonyl Stress in Transgenic Spontaneously Hypertensive Rats Expressing Human C-Reactive Protein. PLoS One. 2016;11(3):e0150924.

68. El Messaoudi S, Nederlof R, Zuurbier CJ, van Swieten HA, Pickkers P, Tallini YN, Choi BR, Breitbach M, Doran X, et al. Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. Am J Physiol Heart Circ Physiol. 2011;301(2):H459–68.

69. Basnet S, Kozikowski A, Sun H, Troup M, Urrutia LE, Pekmezaris R. Metformin deficiency in mouse hearts. FASEB J. 2008;22(4):1204–12.

70. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfield T, Field ME, Fonarow GC, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2018;15(10):e190–252.

71. Prenner SB, Shah SJ, Goldberg JJ, Sauer AJ. Repolarization heterogeneity: beyond the QT interval. J Am Heart Assoc. 2016;5(5):e003607.

72. Nishiyama A, Ishii DN, Backx PH, Pulford BE, Birks BR, Tamkun MM. Altered K(+) channel gene expression in diabetic rat ventricle: isoform switching between Kv4.2 and Kv4.1. Am J Physiol Heart Circ Physiol. 2001;281(4):H1800–7.

73. Shimoni Y, Severson D, Ewart HS. Insulin resistance and the modulation of rat cardiac K(+) currents. Am J Physiol Heart Circ Physiol. 2000;279(2):H639–49.

74. Yada H, Murata M, Shimoda K, Yuasa S, Kaifu K, Ieda M, Adachi T, Nishiyama A, Ishii DN, Backx PH, Silhavy J, et al. Nitric oxide depresses connexin 43 after myocardial infarction in mice. Acta Physiol (Oxf). 2008;194(1):23–33.

75. Yin M, van der Horst IC, van Melle JP, Qian C, van Gilst WH, Siljeh HH, de Boer RA. Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. Am J Physiol Heart Circ Physiol. 2013;310(2):H459–68.

76. Galvart JW, Gundewar S, Jha S, Greer JJ, Bestemmman WH, Tian R, Lefer DJ. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes. 2008;57(3):696–705.

77. Lu L, Ye S, Scalo RL, Reusch JEB, Greyson CR, Schwartz GG. Metformin prevents ischaemic ventricular fibrillation in metabolically normal pigs. Diabetologia. 2017;60(8):1550–8.

78. Costa EC, Goncalves AA, Areas MA, Morgabel RG. Effects of metformin therapy and postoperative atrial fibrillation in diabetic patients after cardiac surgery. J Intensive Care. 2017;5:60.

79. Tran HV, Gore JM, Darling CE, Ash AS, Kiefe CJ, Goldberg BJ. Hyperglycemia and risk of ventricular tachycardia among patients hospitalized with acute myocardial infarction. Cardiovasc Diabetol. 2018;17(1):125.

80. Marfella R, Rossi F, Giugliano D. QTc dispersion, hyperglycemia, and hyperinsulinemia. Circulation. 1999;100(25):e149.

81. Jardine DL, Charles CJ, Frampton CM, Richards AM. Cardiac sympathetic nerve activity and ventricular fibrillation during acute myocardial infarction in a conscious sheep model. Am J Physiol Heart Circ Physiol. 2007;293(1):H433–9.

82. Najeed SA, Khan IA, Molnar J, Somberg JC. Differential effect of glyburide (glibenclamide) and metformin on QT dispersion: a potential adenosine triphosphate sensitive K+ channel effect. Am J Cardiol. 2002;90(10):1103–6.

83. Cacciapuoti F, Spezia R, Bianchi U, Lama D, D’Avino M, Varricchio M. Effectiveness of glibenclamide on myocardial ischemic ventricular arrhythmias in non-insulin-dependent diabetes mellitus. Am J Cardiol. 1991;67(9):843–7.

84. Surinkaev S, Kumphune S, Chattipakorn S, Chattipakorn N. Inhibition of p38 MAPK during atrial fibrillation, but not reperfusion, effectively attenuates fatal arrhythmia in ischemia/reperfusion heart. J Cardiovasc Pharmacol. 2013;61(2):133–41.

85. Jackson PE, Jones DL. Nitric oxide depresses connexin 43 after myocardial infarction in mice. Acta Physiol (Oxf). 2008;194(1):23–33.

86. Van Cauteren S, Lemaire J, Kopp V, Detry J, Pluymers D, Janssens M, et al. Metformin as an Upstream Therapy in Atrial Fibrillation. https://ClinicalTrials.gov/show/NCT03603912.

87. Tran HV, Gore JM, Darling CE, Ash AS, Kiefe CJ, Goldberg BJ. Hyperglycemia and risk of ventricular tachycardia among patients hospitalized with acute myocardial infarction. Cardiovasc Diabetol. 2018;17(1):136.

88. Marfella R, Rossi F, Giugliano D. QTc dispersion, hyperglycemia, and hyperinsulinemia. Circulation. 1999;100(25):e149.

89. Tran HV, Gore JM, Darling CE, Ash AS, Kiefe CJ, Goldberg BJ. Hyperglycemia and risk of ventricular tachycardia among patients hospitalized with acute myocardial infarction. Cardiovasc Diabetol. 2018;17(1):136.

90. Jardine DL, Charles CJ, Frampton CM, Richards AM. Cardiac sympathetic nerve activity and ventricular fibrillation during acute myocardial infarction in a conscious sheep model. Am J Physiol Heart Circ Physiol. 2007;293(1):H433–9.

91. Najeed SA, Khan IA, Molnar J, Somberg JC. Differential effect of glyburide (glibenclamide) and metformin on QT dispersion: a potential adenosine triphosphate sensitive K+ channel effect. Am J Cardiol. 2002;90(10):1103–6.

92. Cacciapuoti F, Spezia R, Bianchi U, Lama D, D’Avino M, Varricchio M. Effectiveness of glibenclamide on myocardial ischemic ventricular arrhythmias in non-insulin-dependent diabetes mellitus. Am J Cardiol. 1991;67(9):843–7.

93. Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF). https://ClinicalTrials.gov/show/NCT03603912.

94. Metformin as an Upstream Therapy in Atrial Fibrillation. https://ClinicalTrials.gov/show/NCT02931253.